Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 20/20 | 0.71 |
| ▸ | JAK3 | P52333 | 20/20 | 0.71 |
| ▸ | JAK2 | O60674 | 15/20 | 0.71 |
| ▸ | JAK1 | P23458 | 15/20 | 0.71 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.67 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21676342 | 0.90 | TYK2 (0.69) | TYK2JAK3JAK2JAK1P2RX3 | |
| SCHEMBL21574332 | 0.90 | TYK2 (0.71) | TYK2JAK3JAK2JAK1P2RX3 | |
| SCHEMBL24594223 | 0.89 | TYK2 (0.70) | TYK2JAK3JAK2JAK1P2RX3 | |
| SCHEMBL21229857 | 0.89 | TYK2 (0.70) | TYK2JAK3JAK2JAK1P2RX3 | |
| SCHEMBL24337003 | 0.89 | TYK2 (0.70) | TYK2JAK3JAK2JAK1P2RX3 | |
| SCHEMBL18269690 | 0.89 | TYK2 (0.70) | TYK2JAK3JAK2JAK1P2RX3 | |
| SCHEMBL29707886 | 0.89 | TYK2 (0.70) | TYK2JAK3JAK2JAK1P2RX3 | |
| SCHEMBL23889259 | 0.88 | TYK2 (0.74) | TYK2JAK3JAK2JAK1P2RX3 | |
| SCHEMBL21229505 | 0.87 | JAK3 (0.69) | TYK2JAK3JAK2JAK1P2RX3 | |
| SCHEMBL18271836 | 0.87 | JAK3 (0.69) | TYK2JAK3JAK2JAK1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725470-B2 | Substituted naphthyridines as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-08-08 | — | — | US | disclosed |